.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Deloitte
US Department of Justice
Medtronic
Citi
Queensland Health
Dow
Covington
Healthtrust
Express Scripts

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Systematic evolution of ligands by exponential enrichment: Chemi-SELEX
Abstract:This application provides methods for identifying nucleic acid ligands capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.
Inventor(s): Gold; Larry (Boulder, CO), Eaton; Bruce (Boulder, CO), Smith; Drew (Boulder, CO), Wecker; Matthew (Boulder, CO), Jensen; Kirk (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster, CA)
Filing Date:Oct 04, 1999
Application Number:09/412,017
Claims:1. A covalent complex between a nucleic acid ligand and a target molecule, wherein said nucleic acid ligand comprises a chemically reactive functional unit, comprising:

a) preparing a candidate mixture of nucleic acids comprising at least one functional unit;

b) contacting said candidate mixture with said target molecule, wherein nucleic acid sequences which bind covalently with said target molecule form nucleic acid-target molecule complexes;

c) partitioning the nucleic acid-target molecule complexes from the remainder of the candidate mixture, whereby a covalent complex may be identified.

2. The covalent complex of claim 1 wherein said nucleic acid ligand is selected from the sequences listed in Tables II and IV.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Cantor Fitzgerald
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot